HACKENSACK, N.J. and PETACH TIKVAH, Israel, June 16, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, is participating in the Israel Pavilion at the invitation of Israel's Office of the Chief Scientist. BrainStorm is one of a small group of Israeli biopharmaceutical, medical device and diagnostics companies selected for participation in the Pavilion by the Israeli Industry Center for R&D (MATIMOP), the Israel Advanced Technology Industries (IATI), and the Office of the Chief Scientist. BrainStorm's CEO, Dr. Tony Fiorino, and Vice President of Cell Production, Dr. Yossef Levy, are attending the convention.
"We are pleased to have the opportunity to represent Israel's biotechnology industry as a participant in the Israel Pavilion, and we are grateful for Office of the Chief Scientist's invitation. The BIO International Convention is the largest industry meeting, and provides for us an excellent opportunity to engage in conversations with potential collaborators and partners," stated Dr. Fiorino.
The BIO International Convention is the world's largest biotechnology industry gathering, allowing companies to participate in key networking and partnering discussions through the BIO Business Forum, to learn current industry, policy and regulatory trends at hundreds of sessions, and features the largest industry exhibition, the BIO Exhibition. The convention is attended by thousands of professionals representing biotechnology and pharmaceutical companies, service providers, industry consultant, academic institutions and government agencies. Additional information on the Israel Pavilion, located at the BIO Exhibition booth 427, can be found at http://www.matimop.org.il/uploads/attachments/35645/israeli_copmany_catalog__bio_2015.pdf.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
SOURCE BrainStorm Cell Therapeutics Inc.